The Global Plaque Psoriasis Market, valued at USD 32.28 Billion in 2025, is projected to exhibit a CAGR of 7.1%, to reach USD 52.17 Billion by 2032.
Market growth is driven by the rising prevalence of psoriasis, increasing adoption of biologic and targeted therapies, and expanding R&D investments in novel immunomodulatory treatments. The introduction of advanced biologics and small-molecule inhibitors, such as IL-23 and TYK2 inhibitors, is reshaping treatment paradigms and improving patient outcomes.
Furthermore, growing awareness about early diagnosis, improved access to dermatological care, and favorable reimbursement policies in developed markets are contributing to the market expansion. Emerging trends such as personalized medicine, biosimilar development, and digital therapeutics for disease management are expected to further enhance growth prospects over the forecast period.
Market Takeaways
Global Plaque Psoriasis Market Report Coverage
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/plaque-psoriasis-market
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 32.28 Billion |
|
Estimated Value by 2032 |
USD 52.17 Billion |
|
Growth Rate |
Poised to exhibit a CAGR of 7.1% |
|
Historical Data |
2020-2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Trends |
|
|
Opportunities |
|
|
Restraints & Challenges |
|
Market Dynamics
The global plaque psoriasis market is witnessing steady growth, driven by the rising prevalence of psoriasis worldwide and increasing adoption of advanced systemic and biologic therapies. Growing awareness of disease management, improved diagnostic rates, and expanding access to innovative treatment options are further accelerating market expansion.
Systemic therapies dominate the treatment landscape, accounting for nearly half of the market share in 2025, supported by the strong clinical efficacy of biologics and targeted small-molecule agents in managing moderate-to-severe cases. In particular, IL-17 and IL-23 inhibitors have shown significant improvements in symptom control and long-term remission, driving their rapid adoption in developed markets.
In March 2024, UCB received the U.S. FDA approval for BIMZELX (bimekizumab-bkzx) for the treatment of moderate-to-severe plaque psoriasis, marking a major milestone in biologic innovation.
Topical therapies remain critical for mild cases, with corticosteroids, vitamin D analogues, and calcineurin inhibitors continuing to dominate early-stage treatment. Meanwhile, phototherapy remains a viable option for patients resistant to topical medications.
However, challenges persist in the form of high treatment costs, biologic therapy access limitations, and adverse effect management. Despite these barriers, ongoing R&D efforts, expanding biologic pipelines, and supportive reimbursement frameworks are expected to sustain strong market growth through 2032, as the therapeutic focus shifts toward personalized, combination, and biologic-based treatment approaches.
Market Trends
Biologic treatments are increasingly becoming the standard for moderate-to-severe plaque psoriasis, driven by better skin clearance and long-term results compared to older systemic or topical treatments.
In July 2025, Johnson & Johnson submitted a Biologics License Application (BLA) to the U.S. FDA for icotrokinra, a first-in-class oral peptide targeting the IL-23 receptor, for the treatment of moderate-to-severe plaque psoriasis. The submission follows successful Phase 3 trial results demonstrating high efficacy, with approximately 65% of patients achieving IGA 0/1 and around 50% reaching PASI 90 at Week 16.
Telemedicine platforms, AI-driven diagnostics, and digital monitoring tools are being adopted more widely in psoriasis care, improving early detection, treatment adherence, and personalized therapy planning.
In July 2025, CareCloud, Inc., a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, today announced the launch of its fully integrated, AI-driven dermatology EHR, designed to streamline clinical workflows and collections, while enhancing patient engagement and improving financial outcomes for dermatology practices.
Market Opportunities
With numerous biologics facing patent expiry and increasing healthcare cost pressures, biosimilars for plaque psoriasis represent a major growth area, enabling broader access and price competition.
In April 2024, Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the FDA had approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.
Digital Health and Patient-Management Tools for Psoriasis Care
Teledermatology platforms, AI-driven diagnostics and digital monitoring systems are being integrated into psoriasis management, offering opportunities for improved adherence, early detection, and personalized therapy planning.
In April 2025, UCB partnered with Smartpatient, the developer of the globally recognized MyTherapy mobile health app, to launch a customized digital health companion for individuals living with psoriasis. The collaboration, debuting in Germany, reflects UCB’s ongoing commitment to improving the lives of people affected by severe diseases through innovative and patient-centered digital partnerships.
Analyst View
Key Development
Competitive Landscape
Plaque Psoriasis Market Segmentation
Regional Insights
Related Reports :